Liquidia Q1 EPS beats estimates as YUTREPIA sales drive profit

Liquidia

11/05/2026 11:38

Overview

US biopharma firm's Q1 revenue rose on YUTREPIA sales, third straight profitable quarter

EPS for Q1 beat analyst expectations

Company saw increased patient uptake and more prescribers for YUTREPIA since launch

Outlook

Company did not provide specific financial or quantitative guidance for future quarters or full year in its press release

Result Drivers

YUTREPIA LAUNCH - Q1 revenue and profitability driven by continued uptake and sales of YUTREPIA following its launch in June 2025

PATIENT UPTAKE - Company reported more than 4,500 unique patient prescriptions and approximately 3,750 patients treated since launch, with strong prescription-to-start conversion rates

Company press release: ID:nGNX7bTPVg

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
Beat
$0.52
$0.41 (8 Analysts)
Q1 Operating Income
$61.5 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Liquidia Corp is $54.00, about 27.7% above its May 8 closing price of $42.30

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 23 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)